
Praxis Precision Medicines, Inc.
- Jurisdiction
United States - ISIN
US74006W2070 (PRAX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Read full profile
Stock price
Fundamentals
- Net revenue
€6.62M - Gross margin
98.8% - EBIT
-€231.65M - EBIT margin
-3,497.6% - Net income
-€214.10M - Net margin
-3,232.6%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: May 9, 2022